{"id":"NCT00528567","sponsor":"Hoffmann-La Roche","briefTitle":"BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer","officialTitle":"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in \"Triple Negative\" Breast Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2012-02","completion":"2014-06","firstPosted":"2007-09-12","resultsPosted":"2013-09-10","lastUpdate":"2015-09-04"},"enrollment":2591,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Standard adjuvant chemotherapy","otherNames":[]}],"arms":[{"label":"Bevacizumab and Chemotherapy","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.\n\nThe secondary objectives of this trial are to:\n\n* compare Overall Survival (OS), Breast Cancer-Free Interval (BCFI), Disease- Free Survival (DFS) and Distant Disease-Free Survival (DDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy in combination with 1 year of bevacizumab\n* evaluate the safety and tolerability of bevacizumab\n\nAn exploratory sub-study (not reported here) was to identify biomarkers (from tumour or serum) predictive of toxicity and for the level of benefit from the addition of bevacizumab to standard adjuvant systemic treatment.","primaryOutcome":{"measure":"Time to Invasive Disease-free Survival (IDFS) Event","timeFrame":"Event driven (until data cutoff: 29 February 2012: up to 49 months)","effectByArm":[{"arm":"Bevacizumab and Chemotherapy","deltaMin":null,"sd":null},{"arm":"Chemotherapy","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1810"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":403,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Canada","China","Costa Rica","Czechia","Finland","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","North Macedonia","Peru","Philippines","Poland","Portugal","Romania","Russia","Serbia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["27993816","23932548"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":379,"n":1288},"commonTop":["Nausea","Alopecia","Stomatitis","Fatigue","Neutropenia"]}}